Vernalis Research specializes in fragment and structure-based drug discovery, focusing on generating cell-active lead compounds and clinical candidates. The company operates in the pharmaceutical and biotechnology sectors, targeting critical areas such as oncology, neurodegeneration, anti-infectives, and inflammation. Vernalis serves a diverse range of clients, including pharmaceutical companies, biotech firms, and academic institutions. The business model revolves around collaborative partnerships and licensing agreements, where Vernalis provides its expertise in drug discovery to develop new therapeutic candidates. Revenue is generated through upfront payments, milestone payments, and royalties from successful drug candidates. The company is headquartered in Cambridge, UK, and boasts a team of experienced scientists working in state-of-the-art research laboratories.

Keywords: drug discovery, oncology, neurodegeneration, anti-infectives, inflammation, fragment-based, structure-based, lead compounds, clinical candidates, partnerships.